Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed) | PA 19 033

Opportunity Information: Apply for PA 19 033

This NIH funding opportunity (PA 19-033) supports Small Business Innovation Research and Small Business Technology Transfer style projects under the R41/R42 mechanisms (with clinical trials not allowed) aimed at turning discoveries from the Illuminating the Druggable Genome (IDG) program into commercially usable products and capabilities. The central idea is to help small business concerns take understudied, potentially druggable proteins highlighted by IDG and move them from basic characterization toward practical, market-ready research tools, validated datasets, and early drug discovery starting points. The IDG program itself is a large consortium effort designed to uncover the functions and therapeutic relevance of lesser-known proteins within the druggable genome, and it generates enabling resources such as data, reagents, and computational tools that still need downstream validation and packaging to become broadly adopted by researchers and industry.

Projects are expected to complement the IDG consortium infrastructure, which includes Data and Resource Generation Centers that produce experimental resources and datasets, a Knowledge Management Center that organizes and integrates knowledge across the program, a Resource Dissemination and Outreach Center that helps distribute and promote resources, and efforts focused on Cutting Edge Informatics Tools. Within that ecosystem, small businesses are positioned to do the practical and commercially oriented work that often sits between an academic resource and a product that customers will reliably pay for. That can mean confirming that an IDG-generated reagent performs consistently across use cases, translating a research-grade assay into a robust kit or service, improving reproducibility and quality control, or building a scalable platform that makes IDG insights easier to apply in real-world drug discovery workflows.

The scope is intentionally broad as long as it stays in the early research and commercialization-enabling lane. Examples of responsive activities include early proof-of-concept demonstrations that an IDG-nominated protein can be measured or perturbed in a meaningful way, development and validation of assays suitable for screening or mechanistic studies, and initial steps toward preclinical drug discovery programs that use IDG targets and resources as the foundation. In practice, that might look like creating validated biochemical or cell-based assays for an understudied kinase, GPCR, ion channel, or epigenetic regulator; developing high-quality antibodies, chemical probes, or other affinity reagents with clear performance data; producing standardized reference datasets or analytical pipelines that make IDG data easier to interpret; or building informatics products that integrate IDG knowledge into target selection and hypothesis generation. The emphasis is on commercial validation and readiness: demonstrating that what IDG has revealed can be turned into something dependable, scalable, and valuable to external users.

Eligibility is limited to small businesses. Non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. That said, the NIH policy framework may allow foreign components in certain cases as defined in the NIH Grants Policy Statement, but the applicant organization itself must meet the small business eligibility requirements and remain U.S.-based. The opportunity is administered by the National Institutes of Health under a discretionary grant program within the health and biomedical research space, tied to multiple CFDA listings (including 93.121 and several others), reflecting that IDG-related work can cut across many NIH institutes and disease areas.

Operationally, the announcement was created on October 24, 2018, with an original closing date listed as September 5, 2021. While specific award ceilings and expected award counts are not provided in the supplied text, the intent is clearly to support early-stage, milestone-driven R&D that reduces technical risk and moves IDG-derived targets and tools closer to products and services that can be sustained beyond federal funding. The overall outcome NIH is seeking is a stronger pipeline from understudied protein biology to practical, widely usable commercial resources, ultimately accelerating discovery and therapeutic development by making hard-to-study parts of the druggable genome more accessible to the broader research community.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.242, 93.350, 93.393, 93.394, 93.395, 93.396, 93.399, 93.879.
• This funding opportunity was created on 2018-10-24.
• Applicants must submit their applications by 2021-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PA 19 033

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: